neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia

AI Briefing

• – Neurocare Group AG receives SFDA MDMA approval for TMS devices in Saudi Arabia, enabling access to non-invasive, evidence-based mental health treatment.
• – This approval is a significant milestone for the company, expanding its presence in the Middle Eastern market.
• – The approved TMS devices are designed to treat various mental health conditions, including depression and anxiety.